Samsung Biologics to acquire PolyPeptide Group AG
삼성물산
028260
Signal Score
Historical Avg Return (5d)
-0.03%
Data Coverage
100%n=666
Risk-adjusted indicator based on 666 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
POSITIVE
Key Numbers
- • Acquisition Amount: 2.706 T KRW
- • Acquired Shares: 33,016,411 Shares
- • Post-acquisition Ownership: 100%
- • Acquisition Amount to Total Assets: 3.13%
- • PolyPeptide Group AG 2023 Revenue: 669.198 B KRW
AI Analysis Summary
Samsung C&T's subsidiary, Samsung Biologics, decided to acquire 100% of PolyPeptide Group AG, a Swiss peptide CDMO company, for 2.706 T KRW. This acquisition, representing 3.13% of Samsung C&T's total assets, aims to strengthen business competitiveness in the peptide CDMO sector. The acquisition is conditional on a minimum tender of 66.7% of PolyPeptide Group AG's fully diluted capital. PolyPeptide Group AG reported 2023 revenue of 669.198 B KRW and a net loss of 36.143 B KRW. The deal is expected to close by November 30, 2026, with funding potentially including debt.
How This Event Is Evaluated
M&A / Merger Evaluation
M&A events are evaluated by assessing deal size relative to company scale, strategic rationale, financing structure, and integration risk.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Deal size relative to market value
- Strategic fit and synergy potential
- Financing structure (cash, stock, debt)
- Regulatory and integration risk
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.